Methylation of the Oxytocin Receptor Gene in Clinically Depressed Patients Compared to Controls: the Role of OXTR rs53576 Genotype

Dr. I. Reiner, M.H. Van IJzendoorn, M.J. Bakermans-Kranenburg, S. Bleich, M. Beutel, H. Frieling

PII: S0022-3956(15)00081-3
DOI: 10.1016/j.jpsychires.2015.03.012
Reference: PIAT 2591

To appear in: Journal of Psychiatric Research

Received Date: 15 January 2015
Revised Date: 16 March 2015
Accepted Date: 17 March 2015


This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
Title page

Methylation of the Oxytocin Receptor Gene in Clinically Depressed Patients Compared to Controls: the Role of OXTR rs53576 Genotype

Reiner, I1, Van IJzendoorn MH2, Bakermans-Kranenburg MJ2, Bleich, S3, Beutel, M1, Frieling, H3.

Affiliation:
1 Department of Psychosomatic Medicine and Psychotherapy University Medical Center; Mainz; Germany
2 Center for Child and Family Studies, Rommert Casimir Institute for Developmental Psychopathology, Leiden University, Leiden, The Netherlands
3 Molecular Neuroscience Laboratory; Department of Psychiatry, Social Psychiatry and Psychotherapy, Hannover Medical School (MHH), Hannover, Germany

RUNNING TITLE:
Methylation Oxytocin Receptor Gene Depression

Corresponding Author:
Dr. Iris Reiner
University Medical Center Mainz
Department of Psychosomatic Medicine and Psychotherapy
Untere Zahlbacher Str. 8; 55131 Mainz; Germany
iris.reiner@unimedizin-mainz.de
Phone: +49-6131-178124
Fax: +49-6131-175563
Abstract

The emerging field of epigenetics provides a biological basis for gene-environment interactions relevant to depression. We focus on DNA methylation of exon 1 and 2 of the oxytocin receptor gene (OXTR) promoter. The research aims of the current study were to compare OXTR DNA methylation of depressed patients with healthy control subjects and to investigate possible influences of the OXTR rs53576 genotype. The sample of the present study consisted of 43 clinically depressed women recruited from a psychosomatic inpatient unit and 42 healthy, female control subjects – mean age 30 years (SD = 9). DNA methylation profiles of the OXTR gene were assessed from leukocyte DNA by means of bisulfite sequencing. Depressed female patients had decreased OXTR exon 1 DNA methylation compared to non-depressed women. The association between depression and methylation level was moderated by OXTR rs53576 genotype. Exon 2 methylation was associated with OXTR rs53576 genotype but not with depression. Our findings suggest exon-specific methylation mechanisms. Exon 1 methylation appears to be associated with depressive phenotypes whereas exon 2 methylation is influenced by genotype. Previously reported divergent associations between OXTR genotype and depression might be explained by varying exon 1 methylation. In order to further understand the etiology of depression, research on the interplay between genotype, environmental influences and exon-specific methylation patterns is needed.

Keywords:
Oxytocin; methylation; depression; OXTR; biomarkers; exon-specific;
Introduction

With a life-time prevalence in the range of 10-15% in the general population, depression is a frequent and serious mental disorder, affecting the subjects’ quality of life in domains such as psychosocial functioning, work productivity, relationship quality, and mortality risk (Lépine and Briley, 2011). In spite of extensive research on both genetic as well as environmental factors contributing to depression, the pathogenic mechanisms leading to depression are largely unknown. The emerging field of epigenetics may provide insights in the molecular pathways between genotype and the phenotype; the aim of the current study was to explore if depression is associated with different methylation patterns of the oxytocin receptor gene (OXTR).

Reviews of studies estimating the heritability of the depressive disorders using behavior-genetic approaches generally propose a range of .30 - .50 and suggest even higher heritability for severe and recurrent forms of depression (Levinson, 2006, Sullivan et al., 2000). Molecular-genetic research of potential genes associated with depression mainly focused on monoamine-related genes. The serotonin-transported-linked polymorphic region (5-HTTLPR) in SLC6A4, the gene that codes for the serotonin transporter, has been of particular interest, leading to ambiguous results (Hoehe et al., 1998, Lotrich and Pollock, 2004, Ogilvie et al., 1996). So far, no specific genetic variant has been reliably identified as single and “direct” risk factor for depression.

Recently, much attention has been given to the neuropeptide oxytocin in research of depression-related feelings such as loneliness and distrust (Lee et al., 2009). Oxytocin operates through the oxytocin receptor that is coded by OXTR, located on chromosome 3p25.3. The OXTR SNP rs53576 comprises a guanine (G) to adenine (A) substitution and has been studied widely in relation to attachment and social behavior. Several studies, mostly
using an A-allele dominant genetic model, indicate that the A-allele is a “risk allele” for reduced levels of empathy and prosociality: Carriers of at least one A-allele have been found to be at higher risk for autism (Wu et al., 2005), mothers with AA- and AG-genotypes portrayed lower maternal sensitivity than homozygote G-allele carriers (Bakermans-Kranenburg and van Ijzendoorn, 2008). Also, A-allele homozygotes (AA) were found to be lonelier (Lucht et al., 2009). In contrast, homozygote G-allele carriers (GG) were found to be more optimistic and (Saphire-Bernstein et al., 2011), and to have better emotional regulation abilities (Rodrigues et al., 2009). Other studies, however, report no association between the \( OXTR \) rs53576 G-allele and prosocial effects (Cornelis et al., 2012, Kawamura et al., 2010) (see for a meta-analysis Bakermans-Kranenburg and van IJzendoorn, 2014). Little is known about the influence of \( OXTR \) rs53576 on major depression: two studies reported no significant relationship between \( OXTR \) rs53576 genotypes and childhood-onset mood disorders (Strauss et al., 2010) or treatment outcome in depressed patients (Mendlewicz et al., 2012). Studies including environmental factors suggested that homozygote G-allele (GG) carriers may be at higher risk for depression (Costa et al., 2009).

Environmental influences may confer a risk to depression by affecting the genome epigenetically (Schroeder et al., 2010). Epigenetics refers to the study of all changes in gene function that are not encoded by the DNA itself; therefore, epigenetic mechanisms concern chemical markers at or alongside the DNA, but not modifications of the genetic code itself. Different forms of epigenetic regulation are known, and two of them are particularly crucial for the understanding of psychiatric diseases: histone modification and DNA methylation. In histone modification, histone proteins compacting DNA strands are chemically modified at the so called “histone tail” through acetylation, phosphorylation, methylation or other posttranslational modifications, which may change the accessibility of the DNA strand (Rodenhiser and Mann, 2006). DNA methylation refers the methylation of Cytosine residues
within a CpG dinucleotide. Formerly it was believed that DNA methylation mainly occurred in CpG dense regions of the genome (CpG islands) that are often associated with the gene promoter region. Today it is known that DNA methylation can also occur outside of CpG islands and throughout the genome, and that intronic CpG methylation or CpG methylation at CpG island shores are also of functional relevance. The former view that DNA methylation within the promoter region leads to gene silencing, has also been challenged recently, as more and more reports also show a positive relation between methylation and expression (Ehrlich and Lacey, 2013). Lately, the interaction between genotypes and DNA methylation has also found increased attendance, as some genotypes can affect DNA methylation throughout the whole genome (Chen et al., 2015).

DNA methylation is an “environmentally responsive” process, reflecting gene-environment interactions (Meaney, 2010), and is therefore of special interest for the pathogenesis of depression. Several animal studies highlight that early life stress may contribute to the development of depression by influencing DNA methylation of genes associated with stress regulation (Murgatroyd et al., 2009, Weaver et al., 2004, Weaver et al., 2005). In humans, methylation of the OXTR promoter region of exon 3 was found to increase within ten minutes of psycho-social stress (Unternaehrer et al., 2012). However, there is no agreement on how increased versus decreased methylation status in different gene segments is associated with OXTR expression. In mice, increased DNA methylation of the OXTR gene promoter was found to be associated with increased OXTR expression (Mamrut et al., 2013). Particularly methylation in CpG site 7, which is located at the SP1 binding sequence, was found to be associated with increased OXTR expression in various brain regions (Harony-Nicolas et al., 2014). In humans however, increased methylation of OXTR exon 1, 2 and 3 was linked with decreased OXTR expression in the temporal cortex in autistic patients vs non-autistic controls.
A reporter-gene study functionally characterizing the *OXTR* promoter showed that DNA methylation of the CpG island spanning exons 1 and 2 was associated with a decreased expression of the reporter-gene product (Kusui et al., 2001).

Taking findings from animal and human studies together, the inhibitory effect of *OXTR* methylation on gene expression is equivocal. Moreover, methylation in different *OXTR* gene fragments and exons may lead to increased and decreased gene expression, respectively. Nonetheless, there is evidence that *OXTR* methylation a) is associated with psychiatric phenotypes in humans and, b) “guides” *OXTR* expression in brain-specific areas. Even though systematic studies on the effects of possible confounders on DNA methylation of *OXTR* are lacking, several factors are known to affect DNA methylation in general. Among those confounders are age (Steegenga et al., 2014), body mass index (Na et al., 2014), antidepressant use (Melas et al., 2012), alcohol consumption (Bönsch et al., 2004), and tobacco smoking (Hillemacher et al., 2008, Zeilinger et al., 2013).

To our knowledge, ours is the first study testing whether depressed patients differ from mentally healthy individuals in *OXTR* methylation levels. We expected that *OXTR* methylation would differ in clinically depressed versus healthy individuals. In order to examine possible molecular genetics influences, we also tested whether differences in methylation is moderated by *OXTR* rs53576 genotype. Due to prior findings on the effect of antidepressants, age, alcohol, body mass index (BMI) and smoking on methylation levels, these variables were included as covariates.

**Methods and Materials**

**Sample**
The study was approved by the Ethics Committee of the State Board of Physicians of Rhineland-Palatinate (Germany). All participants provided their written informed consent to participate in this study. The total sample consisted of 85 premenopausal women aged 19-52 (Mean = 30.1 years, SD = 9.0 years). 58 % (n = 49) of the participants had a high school degree, 38 % (n = 33) secondary education and 4% (n = 3) lower secondary education. All participants were Caucasians fluent in German language. The clinical sample consisted of 43 depressed patients, who were recruited from the inpatient unit of the Department of Psychosomatic Medicine and Psychotherapy, University Medical Centre Mainz. The control group consisted of 42 healthy control subjects who were recruited by flyers and posters and were matched for age and education.

Inclusion criteria for the patient group were the diagnosis of Depression and/or Dysthymia using the German version of the Structured Clinical Interview for DSM-IV Disorders; SCID-I and SCID-II; (Wittchen et al., 1997). Patients with borderline, antisocial or narcissistic personality disorders as well as patients with eating disorders or substance abuse were not eligible. Data collection for the patient group was time of admission. In the control group, women who were currently in psychotherapy or had a mental disorder diagnosis (using SCID-I and SCID-II) were excluded from further study participation. Generally, pregnant and breastfeeding women and subjects who suffered from adrenocorticotropic, gynecological and neurological diseases were excluded. Factors possibly affecting DNA methylation like smoking, alcohol consumption, caffeine/theine consumption, pregnancy or obstetric complications were assessed using a semi-structured interview. The patient group had the following main diagnoses: Major depression (n = 42), dysthymia (n = 1). Comorbid conditions were anxiety disorders (n = 18), dysthymia (n = 8), and depersonalization disorder (n = 4). One subject from the control group could not be genotyped and was therefore
excluded from further data analyses. A description of all variables analyzed as possible confounders is given in table 1.

**Genotyping of OXTR rs53576**

Genomic DNA was isolated from 200 µL frozen human venous blood using the NucleoMag® Blood 200 µL Kit (Macherey & Nagel, Dueren) on a Biomek ® NXP Laboratory Automation Workstation (Beckman Coulter, Brea, CA). The region of interest flanking rs53576 in *OXTR* intron III (ENSG00000180914) was amplified by Touchdown PCR using HotStarTaq ® Master Mix Kit (Qiagen, Hilden), primers gOXTR_{rs53576_F_431} (5’-GGCCACCATGCTCTCCACATCAGTG-3’) and gOXTR_{rs53576_R_432} (5’-TCAGGAGCGTTGGACTGGAGGAGG-3’) and 1 µL gDNA (20 – 80 ng). PCR steps were performed as followed: 97°C 1 min; 95°C 30 sec, 70°C 45 sec, 72°C 60 sec (15 cycles; incr. -1°C); 95°C 30 sec, 60°C 45 sec, 72°C 60 sec (25 cycles); 72°C 5 min. The 237 bp fragment was determined by Sanger sequencing using BigDyeTerminator v3.1 Cycle Sequencing Kit (BDT v3.1) on a 3500xL genetic analyzer (both: AppliedBiosystems, Austin, TX). SNP-genotype rs53576 was analyzed using the Sequence Scanner v1.0 software (AppliedBiosystems, Austin, TX). (AppliedBiosystems, Austin, TX).

Distribution of rs53576 was: 42.9% GG, 48.8% GA, and 8.3% AA. Deviance of allele-frequencies in depressed patients and healthy controls from Hardy-Weinberg Equilibrium as well as differences of allele and genotype frequencies between the groups were tested using the online tool from the Institute for Human Genetics (Helmholtz Center Munich, Germany) available at http://ihg.gsf.de/ihg/snps.html. Neither depressed patients nor healthy controls showed a deviation of genotype frequencies from Hardy-Weinberg-Equilibrium (depressed patients: F_{(1)} = -0.13; P = 0.41; controls: F_{(1)} = -0.09; P = 0.55). Due to the skewed distribution
of genotypes, and in line with previous studies, we used a dominant model contrasting AA/AG vs GG genotypes (Kumsta and Heinrichs, 2013).

**Methylation**

Fasting blood samples for DNA extraction were drawn on admission. Genomic DNA was extracted from whole frozen EDTA-blood with the QIAamp® DNA Blood Mini Kit (QIAGEN AG, Hilden, Germany) according to the manufacturer’s protocol. Afterwards, 500 ng of genomic DNA were modified by sodium-bisulfite using the EpiTect® Bisulfite Kit (QIAGEN AG, Hilden, Germany). Sodium-bisulfite deaminates cytosines in CpG dinucleotides to uracils, whereas methylated cytosines are protected from alteration.

Primers were designed to amplify a region covering three fragments (amplicon 2A, amplicon 2B, amplicon 2C) of the OXTR gene containing 71 CpG sites within exon 1, intron 1 and exon 2. Primer sequences as well as fragment sizes and chromosomal position are listed in table 2.

To amplify a specific product, a nested touchdown PCR was performed (15 cycles of 95°C for 30sec, 63°C-48°C (- 1°C per cycle) for 45sec and 72°C for 60sec ; 25 cycles of 95°C for 30sec, 48°C for 45sec and 72°C for 60sec).

Subsequently each PCR product was visualized on a standard 2.0% agarose gel, followed by purification using Agencourt AMPure XP beads (Beckman Coulter GmbH, Krefeld, Germany). Sequencing was performed using a BigDye® Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems, Foster City, CA, USA) according to the manufacturer’s instructions. A maximum concentration of 50ng purified PCR product was applied for the extension reaction. The oligonucleotides of the second PCR were used as sequencing primers. After dye-terminator removal with Agencourt CleanSEQ System (Beckman Coulter), the
products were analyzed on an Applied Biosystems® 3500xL DNA Analyzer (Applied Biosystems).

The obtained sequences were analysed using the ESME software package that determines the DNA methylation levels from the sequence trace files. ESME performs quality control, normalizes the signals, corrects for incomplete bisulfite conversion, aligns generated bisulfite sequence and reference sequence to compare C to T values (forward sequence) and G to A values (reverse sequence) peaks at CPG-sites (Lewin et al., 2004). Only CpG sites yielding valid results in >70% of all samples were used for further analyses. In fact only 36 CpG sites within exon 1 and 7 CpG sites in exon 2 fulfilled this criterion while no CpG site within intron 1 yielded good enough measurements to be included into the analyses.

**Statistical Analyses**

Statistical analyses were performed using IBM SPSS Statistics 20 (IBM, New York, NY). All variables were normally distributed according to the Kolmogorov-Smirnov test. Therefore, parametric methods were applied. Data are given as mean (SD). All statistical tests were two-tailed with a significance level of $\alpha = 0.05$. Confidence intervals and $p$-values of post-hoc tests were Bonferroni-corrected for multiple comparisons.

To analyse the differences in DNA methylation between patients and controls, linear mixed models were performed for both exons separately. In a first model, the effect of depression on OXTR methylation was checked (dependent variable: methylation; fixed factors: CpG position; depression group; interaction between CpG position and depression group to check, if effects were evenly distributed across the promoter). To assess the effect of the OXTR genotype, this variable was included as fixed factor and interactions between OXTR and depression group were included in the model. In subsequent analyses, effects of possible
confounding variables (age, BMI, smoking, alcohol consumption, antidepressant use) were tested.

**Results**

**Exon 1: Effects of depression on OXTR methylation**

The linear mixed model on methylation level with CpG position and group (patients versus controls) showed a significant main effect of CpG position ($F_{(35;2709)}=73.25; p < 0.001$) and a significant difference between patients and controls ($F_{(1;2709)}=16.26; p < 0.001$) with a decreased level of methylation in the patient group (figure 2a). As no interaction between CpG position and group was observed ($F_{(35; 2709)}=0.91; p = 0.624$), group specific methylation patterns seem to be evenly distributed across exon 1 (figure 2b).

**Exon 1: Genotype x depression interaction**

No significant main effect of the *OXTR* genotype was found (Figure 3a). However, the interaction between group and *OXTR* genotype was significant ($F_{(1;2706)}=4.07; p = 0.044$). Patients homozygous for the G-allele had lower levels of methylation of exon 1 than those carrying at least one A-allele (estimated marginal means (SE): GG: 0.065(0.003) vs. AA/AG: 0.072(0.003)), whereas controls homozygous for the G-allele had higher methylation levels than those carrying at least one A-allele (EMM: GG: 0.082(0.003) vs. AA/AG: 0.077(0.003); Figure 3b).
Exon 2: Effects of OXTR rs53576 on OXTR methylation

We found, again, a significant main effect of the CpG-position ($F_{(6;531)}=91.54; p < 0.001$), but no differences between patients and controls ($F_{(1;531)}=0.512; p = 0.475$; Figure 4a). In a second linear mixed model with OXTR genotype and CpG position as factors we found a significant main effect of OXTR genotype ($F_{(1;529)}=40.63; p < 0.001$; Figure 4b) and a significant interaction between CpG-position and genotype ($F_{(6;529)}=9.95; p < 0.001$; Figure 4c) on exon 2 methylation level. Parameter estimates revealed that this effect was mainly driven by CpG 37 and CpG 39. No significant group by genotype interaction was observed.

Confounding factors

To check for possible confounders, we tested the influence of age, BMI, current antidepressant use, alcohol use (AUDIT sum score) and smoking status (yes/no) on methylation. We found that higher BMI and smoking were associated with lower exon 1 methylation ((BMI: $F_{(1;2701)}=13.64; p < 0.001$; smoking: $F_{(1;2701)}=7.82; p = 0.005$) while exon 2 methylation increased with age ($F_{(1;528)}=4.25; p = 0.04$). Covarying BMI and smoking, and age respectively, the main effects of depressed vs non-depressed group (exon 1: $F_{(1;2704)}=12.55; p < 0.001$) and OXTR genotype (exon 2: $F_{(1;532)}=35.33; p < 0.001$) and the group by genotype interaction (exon 1: $F_{(1;2704)}=4.99; p = 0.026$) remained significant.

Discussion

The research aim of our study was to compare methylation status of the oxytocin receptor gene OXTR in clinically depressed versus non-depressed females. Our main finding was that
exon 1 methylation was significantly decreased in depressed patients; the effect was, however, moderated by OXTR rs53576 genotype. G-allele homozygous patients had decreased exon 1 methylation compared to patient group A-allele carriers. In contrast, in healthy control subjects, G-allele homozygous participants had higher exon 1 methylation than A-allele carriers. Exon 2 methylation was solely influenced by genotype and was lower in G-allele homozygous individuals, independent of clinical status or other environmental factors. Exon-specific methylation patterns, e.g. regarding 5HTTLPR, have been reported in previous studies on lymphoblast cell lines and were also observed in a clinical sample, yet, the underlying mechanisms have not been revealed (37, 38).

Our study suggests that OXTR exon 1 methylation in particular is associated with phenotype traits such as depression, smoking and body weight, whereas exon 2 appears to be more “biologically driven” and less sensitive to environmental factors. Exon 2 methylation might be associated with phenotypes or clinical diagnoses that are less related to socio-emotional and environmental factors, such as autism. OXTR genotype influences both exon 1 and exon 2 methylation and, for exon 1, interacts with depression in the prediction of methylation level. Further research is needed to understand the dynamics between genotype, exon- and CpG-position, and methylation. Our study contributes to the understanding of depression as we, for the first time, report that clinically depressed patients portray specifically decreased methylation in exon 1. This finding raises questions on the association between decreased exon 1 methylation and altered or decreased OXTR expression, which may contribute to disturbed processing of social stimuli as observed in depression.

Several limitations of the present study need to be acknowledged. First, the present sample consisted of adult females before menopause, thus, replication is needed in male samples and female samples after menopause. Compared to other molecular genetic studies, the sample of
this study is relatively small in size, but importantly, it consists of clinically depressed individuals and a carefully matched mentally healthy control group. Longitudinal studies are needed to more fully establish causal relationships between \textit{OXTR} promoter region methylation and depression.

Our findings show that the relation between DNA methylation, gene expression and depression is far more complex than previously appreciated (Baker-Andresen et al., 2013). Further research on \textit{OXTR} methylation in depressive and other clinical groups needs to involve exon-specific analyses to contribute to a deeper understanding of the functional relevance of different exons and CpG positions. Exon-specific methylation may also impact in different ways on central and peripheral oxytocin levels and may explain contradictory results on associations between depression, \textit{OXTR} genotypes, and plasma oxytocin levels (Cyranowski et al., 2008, Ozsoy et al., 2009, Parker et al., 2010). After promising results on the “prosocial and positive emotions enhancing” effect of intranasal administered oxytocin in non-clinical samples, preliminary studies on intranasal administration with depressed samples revealed disappointing results (Mah et al., 2013, Pincus et al., 2010). Although the mechanisms are not fully understood, previous research suggests that the positive impact of intranasal oxytocin administration may be diminished in clinical disorders that are strongly associated with adverse environmental factors and negative socioemotional childhood experiences such as implicated in depression and posttraumatic stress disorder (Bakermans-Kranenburg and Van IJzendoorn, 2013). Based on these findings, we cautiously suggest that the inconsistent effects of the pharmacotherapeutic use of oxytocin might be biologically explained by exon-specific \textit{OXTR} methylation. Future research on oxytocin administration should include exon-specific \textit{OXTR} methylation status to test for a potential mediating influence.
References


Bakermans-Kranenburg MJ, van Ijzendoorn MH. Oxytocin receptor (OXTR) and serotonin transporter (5-HTT) genes associated with observed parenting. Social cognitive and affective neuroscience. 2008;3:128-34.


Levinson DF. The genetics of depression: a review. Biological psychiatry. 2006;60:84-92.


Figure Legends

Figure 1: Scheme of the OXTR gene and associated CpG island

The OXTR gene consists of four exons and a large intronic sequence between exons 1 and 2. The whole region from exon 1 to exon 3 consists of one CpG island. The figure depicts the three PCR fragments sequenced in this study covering the largest part of the CpG island and including exons 1 and 2. Dots mark the position of CpGs that were included into the analysis.

Figure 2: Difference of OXTR exon 1 methylation levels between depressed patients and healthy controls

Patients with depression exhibit reduced methylation levels of OXTR exon 1. (A) estimated marginal means [EMM] derived from mixed linear modelling show a significant lower methylation level in patients (***, p < 0.001; p-value of fixed effect of group (patients vs. controls). (B) mean methylation at every single CpG position of exon 1. Error bars represent standard errors [SEM].

Figure 3: Effect of OXTR rs53576 genotype on methylation levels in exon 1

(A): No differences between A-allele carriers and GG homozygous probands were found for OXTR exon 1 methylation. (B) Differences in OXTR exon 1 methylation between patients and controls are mainly driven by G-homozygous carriers of OXTR rs53576. Statistical details are summarized in the results section.

Figure 4: OXTR exon 2 methylation

(A): No significant effect of depression on OXTR exon 2 methylation occurred, while (B) A-allele carriers exhibit significantly increased methylation levels at exon 2. (C) Significant CpG x genotype interaction, genotype effect on OXTR exon 2 methylation in mainly driven by CpGs 37 and 39.
Bars represent estimated marginal means [EMM] derived from linear mixed modelling, error bars represent standard errors. Further statistical details are summarized in the results section.
Acknowledgements

We would like to express our special thanks to all patients and control subjects for their participation in this study. We also thank the project coordinators Gotje Trojan and Linda Müller-Engling.
### Table 1: Description of study population

<table>
<thead>
<tr>
<th></th>
<th>Patients (n=43)</th>
<th>Healthy Control Women (n=42)</th>
<th>Student's T-test</th>
<th>Fisher's exact test</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Age [yrs]</strong></td>
<td>mean 29.93, SD 8.959, min 19, max 49</td>
<td>mean 30.36, SD 9.146, min 20, max 52</td>
<td>T -0.217 df 83 P 0.828</td>
<td></td>
</tr>
<tr>
<td><strong>BMI [kg/m²]</strong></td>
<td>mean 25.0113, SD 12.4376, min 17.21, max 101.01</td>
<td>mean 23.8447, SD 5.06205, min 17.24, max 38.74</td>
<td>T 0.564 df 83 P 0.574</td>
<td></td>
</tr>
<tr>
<td><strong>AUDIT sum score</strong></td>
<td>mean 3.44, SD 3.534, min 0, max 18</td>
<td>mean 4.14, SD 3.324, min 0, max 18</td>
<td>T -0.802 df 83 P 0.425</td>
<td></td>
</tr>
<tr>
<td><strong>Smoking</strong></td>
<td>yes 14, % 32.56, no 29, % 67.44</td>
<td>yes 12, % 28.57, no 30, % 71.43</td>
<td>P 0.815</td>
<td></td>
</tr>
<tr>
<td><strong>Antidepressant use</strong></td>
<td>yes 14, % 32.56, no 30, % 67.44</td>
<td>yes 0, % 0, no 42, % 100</td>
<td>P &lt;0.001</td>
<td></td>
</tr>
</tbody>
</table>
Table 2: Primers and positions of OXTR fragments

<table>
<thead>
<tr>
<th>Fragment</th>
<th>PCR</th>
<th>Primer</th>
<th>Sequence</th>
<th>Tm (°C)</th>
<th>Position in relation to Exon 1 (bp)</th>
<th>Product size (bp)</th>
<th>Location on Chromosome 3 (alternate assembly HuRef)</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>1A</td>
<td>OXTR_A_F1_80</td>
<td>TTATTGAAAAATAAATTATTATTGTTAGG</td>
<td>56</td>
<td>-21 to +405</td>
<td>427</td>
<td>&gt;gi</td>
</tr>
<tr>
<td></td>
<td></td>
<td>OXTR_A_R2_83</td>
<td>CCCCTACTTAACCCAACCTACCT</td>
<td>65</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>2A</td>
<td>OXTR_A_F2_82</td>
<td>AATTTATTGTTAAGGTTTGGGA</td>
<td>55</td>
<td>-8 to +400</td>
<td>409</td>
<td>&gt;gi</td>
</tr>
<tr>
<td></td>
<td></td>
<td>OXTR_A_R1_81</td>
<td>ACTTAACCCAACCTACCTACCC</td>
<td>64</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>B</td>
<td>1B</td>
<td>OXTR_B_F1_88</td>
<td>GGTGATAGGTGGTGTGGTATAAG</td>
<td>63</td>
<td>+376 to +694</td>
<td>318</td>
<td>&gt;gi</td>
</tr>
<tr>
<td></td>
<td></td>
<td>OXTR_B_R2_91</td>
<td>CTCTAAAAAAACCCCTACCTCA</td>
<td>60</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>2B</td>
<td>OXTR_B_F2_90</td>
<td>GTAGGTAGTGGTGTTAAGTAGGG</td>
<td>66</td>
<td>+379 to +682</td>
<td>303</td>
<td>&gt;gi</td>
</tr>
<tr>
<td></td>
<td></td>
<td>OXTR_B_R1_89</td>
<td>CCCCTACCTCAAAACCCCAAATAC</td>
<td>64</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>C</td>
<td>1C</td>
<td>OXTR_C_F1_84</td>
<td>GGGGAAGGATTAGTGGGTTTGGT</td>
<td>65</td>
<td>+780 to +1205</td>
<td>425</td>
<td>&gt;gi</td>
</tr>
<tr>
<td></td>
<td></td>
<td>OXTR_C_R2_87</td>
<td>AAAACCCAACCTACCTAAAACA</td>
<td>56</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>2C</td>
<td>OXTR_C_F2_86</td>
<td>TAGAGTGGGTTTTTTAGGTA</td>
<td>58</td>
<td>+789 to +1198</td>
<td>409</td>
<td>&gt;gi</td>
</tr>
</tbody>
</table>
Highlights

- We study DNA OXTR methylation in clinically depressed patients
- We report exon-specific methylation patterns of OXTR
- Depression is associated with decreased OXTR exon 1 methylation
- OXTRrs53576 genotype is associated with OXTR exon 2 methylation
- OXTRrs53576 genotype and methylation patterns are interacting
Contributors

IR and HF designed the study; IR conducted data collection and the main literature search and wrote the first draft of the paper. HF was responsible for lab experiments and statistical analyses. IR, MI, MB and HF developed the conceptual idea of the paper. MI and MB provided critical feedback on the manuscript, suggested additional analyses and critical revisions, and edited the manuscript for clarity and precision. SB and MB contributed to the data analyses and interpretation and assisted with text editing. All authors read and approved the final version of the manuscript.
Role of the funding source

This research was supported by MAIFOR, a grant from the University Medical Mainz and the Koehler-Foundation Germany. Study sponsors were not involved in any aspect of study design; collection, analysis, or interpretation of data; preparation of the manuscript; or in the decision to submit the manuscript for publication.